Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01LOE
|
|||
| Former ID |
DNCL002886
|
|||
| Drug Name |
LY2963016
|
|||
| Indication | Type-1/2 diabetes [ICD-11: 5A10-5A11] | Phase 3 | [1] | |
| Company |
Boehringer Ingelheim Pharmaceuticals; Eli Lilly
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02302716) A Study of LY2963016 Compared to LANTUS in Adult Participants With Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||
| REF 2 | Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus ) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab.2015 Aug;17(8):726-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.